

**From:** Bayer US Medical Affairs (no-reply@mail.bayer.com)  
**To:** HCP Email Address

**Subject #1:** Update From Bayer Women's Healthcare Medical Affairs  
**Super Subject #1:** Learn About an Ongoing Trial, Publications, On-Demand CEs, Upcoming Congresses, and More

Learn About an Ongoing Trial, Publications, On-Demand CEs, Upcoming Congresses, and More [View Online](#)

## Women's Healthcare


Medical Affairs Updates  
February 2026



Welcome to Bayer Medical Affairs Women's Healthcare February 2026 Updates. Bayer, a leader in Women's Healthcare, recognized *December 6* as the 25th anniversary of the initial FDA approval of Mirena®. Mirena is a progestin-containing intrauterine system (IUS), approved by the FDA on December 6, 2000. Mirena is currently approved for the prevention of pregnancy for up to 8 years and is also indicated for the treatment of heavy menstrual bleeding (HMB) for women who choose to use intrauterine contraception as their method of contraception for up to 5 years.

Below you will find information on a currently enrolling trial, recent publications supported by Bayer, accredited continuing education programs, upcoming congresses and philanthropy related to the Bayer Women's Healthcare portfolio.

## Currently Enrolling Trial




Bayer Women's Healthcare Medical Affairs is currently enrolling participants in the following clinical trial:





**SUNFLOWER (NCT06904274):**

- **Study Objective:** A phase 3 investigational study evaluating the efficacy and safety of 52-mg levonorgestrel-releasing intrauterine system MIRENA® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.
- **Eligibility Criteria:** Post-menarchal women (≥18 years) at the time of signing the informed consent with histologically confirmed NAEH independent of their parity or menopausal status.

The clinical trial presented is being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.


## Recent Publications Supported by Bayer



<b>Briggs P, et al.</b>	<a href="#">The burden of sleep disturbances and vasomotor symptoms on work productivity, activity impairment and healthcare resource use in perimenopausal and postmenopausal women</a> –  Global Study	<i>Maturitas</i> (December 2025)
<b>Klinghardt M, et al.</b>	<a href="#">Use of oral medications prior to IUD insertion - trends and associations of patient characteristics in a large observational study in Europe (EURAS-LCS12)</a> –  Global Study	<i>Eur J Obstet Gynecol Reprod Biol</i> (December 2025)
<b>Wilkinson T, et al.</b>	<a href="#">Designing and evaluating a statewide person-centered contraceptive access initiative: the PATH4YOU program</a> –  US Study	<i>Contraception</i> (December 2025)
<b>Soares C, et al.</b>	<a href="#">The burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe</a> –  Global Study	<i>Menopause</i> (November 2025)

For additional publications, please visit [medicalaffairs.bayer.com](https://medicalaffairs.bayer.com)

## Accredited Continuing Education



This information is being offered for your educational purposes only. Bayer is not responsible for, nor has any control over, the content presented by any independent website or entity.

### Menopause

#### Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Upon completion of this activity, participants should be able to:

- Explain the health burden associated with vasomotor symptoms (VMS) in menopause and the risk/benefit profile of hormonal therapy
- Examine the efficacy and safety data for novel nonhormonal therapies in the treatment of bothersome menopause symptoms, including VMS and sleep disturbances
- Explore the health care resource utilization and economic burden associated with VMS and the need for a personalized treatment approach to improve menopause-related quality of life

**1.5-hour on-demand video. Available until April 10, 2026**

[CLICK TO ACCESS](#)

#### From Hot Flashes to Sleepless Nights: Evolving Strategies for Navigating the Full Range of Menopause Symptoms

Upon completion of this activity, participants should be able to:

- Have increased knowledge regarding the latest advances related to managing the spectrum of menopause symptoms
- Have greater competence related to assessing severity of symptoms to identify patients with menopause-associated symptoms
- Demonstrate greater confidence in their ability to evaluate the latest advances related to emerging nonhormonal treatments in managing the spectrum of menopause-related symptoms

**1-hour on-demand video. Available until May 28, 2026**

[CLICK TO ACCESS](#)

### Contraception

#### A Snapshot into Women's Health: Managing Intrauterine Contraception, Placement Pain, and Anxiety for Optimal Patient Outcomes

Upon completion of this activity, participants should be able to:


- Assess the range of pain and anxiety experienced by patients undergoing IUD procedures and apply a structured algorithm to evaluate individual risk factors and select appropriate pain management strategies
- Design and implement a multimodal approach to pain management for IUD placement that integrates best practices, including pharmacological and non-pharmacological interventions, to optimize patient comfort and experience

**0.5-hour on-demand video. Available until July 30, 2026**

[CLICK TO ACCESS](#)

For additional accredited continuing education, please visit [medicalaffairs.bayer.com](https://medicalaffairs.bayer.com)

## Congress Calendar




### February 2026

→ **Nurse Practitioner Associates for Continuing Education (NPACE)**  
February 23-25, Nashville, TN  
[NPACE](#)

### March 2026

→ **American Medical Women's Association (AMWA)**  
March 27-29, San Francisco, CA  
[AMWA](#)

 **Poster Presentation:** Efficacy of elinzanetant on menopause-related vasomotor symptoms/sleep disturbance in US African American women: pooled analysis from 2 Phase 3 trials  
**Date/Time:** March 27, 2026 | 11:30 AM-1:00 PM PST  
**Session Name:** Physician and Resident Poster Session  
**Authors:** Genevieve Neal-Perry, Rebecca Dunsmoor-Su, Andrew Trigg, Sydney Lane\*, Ayman Al Hendy, Pauline M. Maki

→ **American Pharmacists Association (APhA)**  
March 27-30, Los Angeles, CA  
[APhA](#)

 **Poster Presentation:** Efficacy of elinzanetant on menopause-related vasomotor symptoms/sleep disturbance in US African American women: pooled analysis from 2 Phase 3 trials  
**Date/Time:** March 28, 2026 | 1:00-3:00 PM PST  
**Session Name:** Meet the Researchers  
**Authors:** Genevieve Neal-Perry, Rebecca Dunsmoor-Su, Andrew Trigg, Inger Britt Carlsson\*, Ayman Al Hendy, Pauline M. Maki

## Philanthropy



### Bayer US Patient Assistance Foundation

Bayer US **Patient Assistance Foundation** is a charitable organization that helps eligible patients get Bayer prescription medicine at no cost. If your patient cannot afford their prescription medication, Bayer may be able to help. Please have your patient contact the program at 1-866-2BUSPAF (228-7723) Monday-Friday, 9:00 AM-6:00 PM EST, or visit the foundation website at [www.patientassistance.bayer.us](https://www.patientassistance.bayer.us) to see if they might qualify for assistance.

### Other Research and Educational Resources

Bayer's US Medical Affairs website is an educational resource for US healthcare providers to access scientific and clinical information. Available at [medicalaffairs.bayer.com](https://medicalaffairs.bayer.com).

For additional information in the following areas, please visit these websites below:

[VMS due to Menopause](#)

[IUD Education](#)

If you have any questions, visit <https://askmed.bayer.com>.

 © 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer. All rights reserved.

Bayer Corporation, 100 Bayer Boulevard, Whippany, NJ 07981  
February 2026. MA-PFM-WHC-US-0139-1

Please note that this email address is not monitored for replies.

[Terms of Use](#) | [Privacy Policy](#) | [Unsubscribe](#)

This message is brought to you by Bayer US Medical Affairs.